FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366608967> ?p ?o ?g. }

• W4366608967 endingPage "216181" @default.
• W4366608967 startingPage "216181" @default.
• W4366608967 abstract "P-glycoprotein (P-gp/ABCB1)-mediated multidrug resistance (MDR) in cancers severely limit chemotherapeutic efficacy. We recently reported that phosphatidylinositol-3-kinase (PI3K) 110α and 110β subunits can be novel targets for reversal of P-gp mediated MDR in cancers, and BAY-1082439 as an inhibitor specific for PI3K 110α and 110β subunits could reverse P-gp-mediated MDR by downregulating P-gp expression in cancer cells. However, BAY-1082439 has very low solubility, short half-life and high in-vivo clearance rate. Till now, nano-system with the functions to target PI3K P110α and P110β and reverse P-gp mediated MDR in cancers has not been reported. In our study, a tumor targeting drug delivery nano-system PBDF was established, which comprised doxorubicin (DOX) and BAY-1082439 respectively encapsulated by biodegradable PLGA-SH nanoparticles (NPs) that were grafted to gold nanorods (Au NRs) modified with FA-PEG-SH, to enhance the efficacy to reverse P-gp mediated MDR and to target tumor cells, further, to enhance the efficiency to inhibit MDR tumors overexpressing P-gp. In-vitro experiments indicated that PBDF NPs greatly enhanced uptake of DOX, improved the activity to reverse MDR, inhibited the cell proliferation, and induced S-phase arrest and apoptosis in KB-C2 cells, as compared with free DOX combining free BAY-1082439. In-vivo experiments further demonstrated that PBDF NPs improved the anti-tumor ability of DOX and inhibited development of KB-C2 tumors. Notably, the metastasis of KB-C2 cells in livers and lungs of nude mice were inhibited by treatment with PBDF NPs, which showed no obvious in-vitro or in-vivo toxicity." @default.
• W4366608967 created "2023-04-23" @default.
• W4366608967 creator A5002918339 @default.
• W4366608967 creator A5010019122 @default.
• W4366608967 creator A5012789104 @default.
• W4366608967 creator A5013793018 @default.
• W4366608967 creator A5017825677 @default.
• W4366608967 creator A5030764071 @default.
• W4366608967 creator A5038005857 @default.
• W4366608967 creator A5042533031 @default.
• W4366608967 creator A5044867727 @default.
• W4366608967 creator A5062841309 @default.
• W4366608967 creator A5069100532 @default.
• W4366608967 date "2023-06-01" @default.
• W4366608967 modified "2023-10-16" @default.
• W4366608967 title "A multi-functional nano-system combining PI3K-110α/β inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency" @default.
• W4366608967 cites W1843302206 @default.
• W4366608967 cites W1963987641 @default.
• W4366608967 cites W1973108158 @default.
• W4366608967 cites W2015828638 @default.
• W4366608967 cites W2019204220 @default.
• W4366608967 cites W2029071448 @default.
• W4366608967 cites W2038271205 @default.
• W4366608967 cites W2056772956 @default.
• W4366608967 cites W2061643831 @default.
• W4366608967 cites W2066076463 @default.
• W4366608967 cites W2070005495 @default.
• W4366608967 cites W2082469106 @default.
• W4366608967 cites W2085242577 @default.
• W4366608967 cites W2142821574 @default.
• W4366608967 cites W2153283071 @default.
• W4366608967 cites W2174426194 @default.
• W4366608967 cites W2330434552 @default.
• W4366608967 cites W2381727044 @default.
• W4366608967 cites W2485653171 @default.
• W4366608967 cites W2562206761 @default.
• W4366608967 cites W2761859208 @default.
• W4366608967 cites W2782405156 @default.
• W4366608967 cites W2789078890 @default.
• W4366608967 cites W2792925067 @default.
• W4366608967 cites W2795895101 @default.
• W4366608967 cites W2795904039 @default.
• W4366608967 cites W2800108104 @default.
• W4366608967 cites W2804333856 @default.
• W4366608967 cites W2883450822 @default.
• W4366608967 cites W2883669595 @default.
• W4366608967 cites W2883744836 @default.
• W4366608967 cites W2884371797 @default.
• W4366608967 cites W2889054280 @default.
• W4366608967 cites W2895090015 @default.
• W4366608967 cites W2895576710 @default.
• W4366608967 cites W2898712541 @default.
• W4366608967 cites W2901265038 @default.
• W4366608967 cites W2902561545 @default.
• W4366608967 cites W2904561538 @default.
• W4366608967 cites W2923057410 @default.
• W4366608967 cites W2930444268 @default.
• W4366608967 cites W2942859808 @default.
• W4366608967 cites W2944725533 @default.
• W4366608967 cites W2950442272 @default.
• W4366608967 cites W2965086491 @default.
• W4366608967 cites W2973199885 @default.
• W4366608967 cites W2977303957 @default.
• W4366608967 cites W2985172372 @default.
• W4366608967 cites W2990901194 @default.
• W4366608967 cites W3002993580 @default.
• W4366608967 cites W3003452994 @default.
• W4366608967 cites W3004667471 @default.
• W4366608967 cites W3007309127 @default.
• W4366608967 cites W3007367983 @default.
• W4366608967 cites W3007492121 @default.
• W4366608967 cites W3009337396 @default.
• W4366608967 cites W3009982233 @default.
• W4366608967 cites W3012295779 @default.
• W4366608967 cites W3019363957 @default.
• W4366608967 cites W3030489061 @default.
• W4366608967 cites W3032966509 @default.
• W4366608967 cites W3034552024 @default.
• W4366608967 cites W3037265638 @default.
• W4366608967 cites W3040057801 @default.
• W4366608967 cites W3088838661 @default.
• W4366608967 cites W3093256416 @default.
• W4366608967 cites W3095291274 @default.
• W4366608967 cites W3113350700 @default.
• W4366608967 cites W3125233656 @default.
• W4366608967 cites W3125519154 @default.
• W4366608967 cites W3135199061 @default.
• W4366608967 cites W3135465357 @default.
• W4366608967 cites W3138574511 @default.
• W4366608967 cites W3140395279 @default.
• W4366608967 cites W3143831139 @default.
• W4366608967 cites W3157704195 @default.
• W4366608967 cites W3164577482 @default.
• W4366608967 cites W3165657312 @default.
• W4366608967 cites W3170839452 @default.
• W4366608967 cites W3192447201 @default.
• W4366608967 cites W3193787845 @default.
• W4366608967 cites W3198278625 @default.

• next